

A light blue world map is centered in the background. Overlaid on the map are several large, semi-transparent arrows: a blue arrow pointing down from the top left, a yellow arrow pointing right from the center, and a grey arrow pointing up from the bottom left.

Results Pack

Financials for Q1 2011

25th April 2011

Performance Highlights

INR Million

- Consolidated Revenue at Rs 4,981 Mn, **31% Growth** over Q1'10 (Rs 3,815 Mn)
- Consolidated EBITDA at Rs 1,023 Mn, **19% Growth** over Q1'10 (Rs 859 Mn)
- Consolidated PBT at Rs 540 Mn, **7% Growth** over Q1'10 (Rs 503 Mn)
- Consolidated PAT (Before Minority) at Rs 451 Mn, **5% Growth** over Q1'10 (Rs 431 Mn)

Q1'2010			Segment	Q1'2011			Revenue Growth
Revenue	EBITDA	%		Revenue	EBITDA	%	%
1,227	428	35%	Specialties	2,374	733	31%	93%
2,588	431	17%	Pharma	2,607	290	11%	1%
3,815*	859	23%	Total	4,981 *	1,023	21%	31%

* Includes Licensing Income of Rs 1,121 Mn (Rs 834 Mn in Q1-10)



Research & Development

Regulated Market	Pharma		Specialties		Total	
	No Of Filings	No of approvals	No Of Filings	No of approvals	No Of Filings	No of approvals
USA	38	20	115	35	153	55
South Africa	40	11	70	25	110	36
Europe ¹	59	55	36	8	95	63
Australia ²	121	118	25	13	146	131
Canada	0	0	6	5	6	5
New Zealand	1	1	3	1	4	2
WHO	16	10	0	0	16	10
Sub Total	275	215	255	87	530	302

Emerging Markets	Pharma		Specialties		Total	
	No Of Filings	No of approvals	No Of Filings	No of approvals	No Of Filings	No of approvals
Africa	392	248	73	43	465	291
French Africa	272	208	75	68	347	276
Latin America	151	121	175	132	326	253
South East Asia	126	95	95	60	221	155
ROW	16	4	65	10	81	14
Sub Total	957	676	483	313	1440	989

Grand Total	1232	891	738	400	1970	1291
--------------------	-------------	------------	------------	------------	-------------	-------------

Note:

1. Includes National filings marketing authorisations (MAs)

2 Includes local marketing authorisations

